It seems what they are attempting to sell is a IP protection service: let us show you other molecules and synesis routes you should also patent defensively, without actually attempting them in practice. Pretty soon you will have algorithmically defined patents.
It's IP anti-science at it's worst.
Which to be fair is probably very unlikely given how healthcare costs and whatnot work in America. Can always bump the price up to compensate for expenses.
BUT - this is still a very useful tool for locating possibly cheaper/simpler methods of producing drugs that have expired protections. There is a project out there that is working on a bioreactor kit that allows the safe home production of several common drugs that are not patent protected. There are also projects that could have been life saving but were already not financially viable that could be rescued by this program.
And if someone is fast enough and has the funds to burn, they could patent some of those processes and then do what Tesla did with their patents.
I think this may open up more opportunities in the long run than it closes.
Apparently the income of Big Pharma investors is more important than the affordability of generics.
You say this as if it is surprising.
So the literature search is to find out what's possible. Among the possibilités, the only ones of interest are those that are not covered in patents, hence the second screen.
On the other hand, if you want to find new processes and compounds that aren't patented, then finding a past expired patent covering a part of the process would mean that part of the process is "safe" (not finding one might mean it is safe, or might mean you've overlooked something)
As you can imagine there are thousands of ways a moderately complex molecule could be deconstructed and the bank of known reactions is more than any one person can really grasp. That and the myriad patent literature and how cryptic and dense it can be make the problem particularly suited for algorithmic treatment. This is only being done now because cataloging all the research and patent literature (which goes back to the late 1800s) and digitally formatting in a way that allows it to be computationally analyzed and processed requires manual translation of each report by a human being. Not many people have the expertise required for this and those that do usually prefer less menial work. So it has taken this long to amass a digital library of sufficient size to give one confidence that the answers it provides are comprehensive and that further searching would be pointless.